Sensitizing effects of bisphosphonate to radiotherapy and chemotherapy in urologic cancers.
| Project/Area Number |
23791745
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
KIJIMA Toshiki 東京医科歯科大学, 医学部附属病院, 医員 (90569500)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | ビスホスホネート / 放射線治療 / 化学療法 / 泌尿器癌 / 放射線療法 / 腎細胞癌 / 前立腺癌 / 膀胱癌 |
|---|
| Research Abstract |
We revealed that STAT1 is one of the key factors regulating intrinsic resistance to cancer therapy in urologic cancers, including renal cell carcinoma, bladder cancer, and prostate cancer. Bisphosphonate was shown to sensitize urologic cancer cells to radiotherapy and chemotherapy by downregulating STAT1 at protein level. These results will contribute to establish the novel combination therapy and to improve the treatment outcomes of both these urologic cancers and other cancers which express STAT1.
|
Report
(3 results)
Research Products
(3 results)
